1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Lasa Supergenerics Limited

Lasa Supergenerics Limited

LASA.BO
Lasa Supergenerics LimitedIN flagBombay Stock Exchange
7.33
INR
-0.17
- -
359.56MMarket Cap
Lasa Supergenerics Limited
LASA.BO
(Bombay Stock Exchange)

Recent

price

7.33

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
- -
96.35
107.13
74.16
41.12
49.76
27.26
25.86
20.84
28.48
5.01
5.02
Revenue per Share
- -
1.15
5.43
-5.26
0.89
5.6
-1.06
-7.71
-4.34
-2.95
-6.8
-6.8
Basic EPS, GAAP
-0.15
-2.27
-2.79
12.83
3.2
8.54
1.83
-3.45
0.03
-0.58
-0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-0.3
15.19
9.83
10.81
15.1
12.79
4.94
0.62
10.02
9.99
10
Book Value per Share
- -
33.62
48.87
43.31
33.25
37.73
28.06
17.46
14.13
12.76
6.57
6.58
Tangible Book Value per Share
23
21
23
23
41
41
50
50
50
50
50
50
Basic Weighted Avg Shares
- -
1,988
2,435
1,696
1,673
2,024
1,371
1,296
1,043
1,424
251
251
Sales/Revenue/Turnover
- -
19.17
9.49
-4.44
9.32
15.54
1.7
-13.97
-8.15
-4.24
-53.24
-53.24
Operating Margin (%)
- -
77
182
193
173
158
145
134
107
123
60
60
Depreciation Expense
- -
24
123
-120
36
228
-53
-386
-217
-148
-341
-341
Net Income, GAAP
- -
- -
18.99
- -
23.39
22.76
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
1.19
5.07
-7.09
2.17
11.25
-3.89
-29.81
-20.83
-10.36
-135.6
-135.6
Profit Margin (%)
- -
94
19
-213
- -
238
215
-35
-110
154
-63
-63
Working Capital
- -
807
603
457
141
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
755
1,173
1,053
1,415
1,589
1,579
1,183
967
837
496
496
Total Equity
- -
- -
8.74
- -
6.25
13.09
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
15.1
- -
9.17
27.78
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-42.22
10.92
43.24
-8.48
-86.73
-156.02
-55.45
-68.04
-68.04
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
73
- -
97
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
50
- -
50
Market Capitalization
581
469
285

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
124
- -
104
Cash, Cash Equivalents & STI
7
- -
7
Accounts Receivable, Net
16
- -
- -
Inventories
42
- -
18
Total Current Liabilities
158
- -
168
Payables & Accruals
- -
- -
- -
ST Debt
73
- -
97
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-19.63%
-40.72%
Free Cash Flow
-151.99%
-469.08%
-97.44%
Net Income, GAAP
- -
111.24%
131.01%
Sales/Revenue/Turnover
- -
-20.61%
-82.35%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
306
243
267
228
1,043
2025
308
394
331
391
1,424
2026
200
31
22
-1
251

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.99
- -
-0.29
- -
-4.34
2025
-0.55
-0.64
1.1
-2.85
-2.95
2026
-4.22
-1.25
-0.51
-0.83
-6.8

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Groove Botanicals, Inc. (GRVE)
Jiuzhitang Co., Ltd. (000989.SZ)
Mercury Biopharmaceutical Corporation (6932.TWO)
Acreage Holdings, Inc. (ACRDF)
Nika Pharmaceuticals Inc. (NIKA)
Cipher Pharmaceuticals Inc. (CPHRF)
Business
Lasa Supergenerics Limited Lasa Supergenerics Limited engages in the research, manufacture, and marketing of active pharmaceutical ingredients (APIs), animal feed ingredients, and reagents for therapeutic use primarily in the veterinary and human healthcare sectors. The company offers a range of API products including fenbendazole, albendazole, ricobendazole, oxfendazole, closantel base and sodium dihydrate, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, toldimphos sodium, cyromazine, and 2,6-diiodo-4-nitrophenol; other API products; animal feed ingredients such as calcium iodate; and reagents like potassium iodide. It specializes in catalyst chemistry for anthelmintic and veterinary APIs, operates a vertically integrated model from discovery to delivery using Good Manufacturing Practice (GMP) standards, and exports to developing markets across multiple countries. Founded in 2016 and headquartered in Ratnagiri, Maharashtra, India, with manufacturing facilities in Mahad and Lote Parshuram, the company maintains alliances with leading Indian and global animal healthcare conglomerates. In recent developments, Lasa Supergenerics experienced a major fire at its primary manufacturing facility in May 2025, which destroyed inventories and equipment valued at Rs 1,973.62 crore, halted all production operations, and contributed to a net loss of Rs 2,821.93 crore for the second quarter ended September 30, 2025. The company reported additional net losses, including Rs 62.52 million for Q2 FY26 and Rs 273.71 million for the first half of FY26, alongside resignations of multiple independent directors—such as Mr. Ajay Sukhwani, Ms. Ekta Gurnasinghani, and Mr. Hardesh Tolani in July-August 2025—and its company secretary Mrs. Mitti Jain in August 2025, citing non-operational status; it responded by appointing four new independent directors effective August 5, 2025, including experts in agro-veterinary sciences, poultry operations, animal care, and nutrition. Lasa Supergenerics explores contract manufacturing and facility leasing to resume operations pending regulatory approvals.